文献速递银屑病与炎症性皮肤病

斑块状银屑病停用生物制剂后出现脓疱型银屑病发作的临床特征与危险因素

Clinical characteristics and risk factors for a distinct pustular psoriasis flare after withdrawal of biologics in plaque psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2026-09-25

多中心研究纳入2011至2025年间对生物制剂应答后停药的患者治疗疗程,分析一种独特的脓疱型银屑病发作。该发作见于86/1198个疗程(7.2%),表现为下肢为主疼痛性弥漫性红斑伴脓疱和肿胀。停药-复发循环次数越多发作越频繁,家族史、合并银屑病关节炎、既往该表型发作、既往停药-复发次数多及达到PASI 50时间长为独立相关因素。

要点

  • 生物制剂停药后脓疱型发作见于7.2%治疗疗程,以下肢疼痛性红斑脓疱为特征。
  • 既往停药-复发循环次数越多,该脓疱型发作风险越高。
  • 有家族史、银屑病关节炎、既往该表型发作等高危患者需警惕并早恢复治疗。

核心结论

  • 停用生物制剂后可出现一种独特的脓疱型银屑病发作,表现为下肢为主的疼痛性弥漫性红斑、脓疱和肿胀。
  • 多个基线及治疗相关因素与该脓疱型发作独立相关,高危患者应警惕监测并早期恢复治疗。

研究设计与样本

  • 多中心研究,纳入2011至2025年间对生物制剂应答后停药患者的治疗疗程,共1198个疗程。
  • 采用广义估计方程模型评估与该脓疱型发作相关的因素。

主要发现

  • 该脓疱型银屑病发作发生于86/1198个治疗疗程(7.2%)。
  • 发作特征为疼痛性、弥漫性、强烈红斑伴脓疱和肿胀,主要累及下肢。
  • 随着生物制剂停药-复发循环次数增加,该发作的发生率升高。

关键数值与推荐

  • 独立相关因素包括:银屑病家族史、合并银屑病关节炎、既往该脓疱型发作表型、既往停药-复发次数较多、生物制剂治疗期间达到PASI 50所需时间较长。

临床怎么用

  • 对具有上述危险因素的患者,停用生物制剂后应警惕监测该脓疱型发作。
  • 建议对高危患者早期恢复治疗。

局限性

  • 治疗分配非随机化。
  • 缺乏组织学和分子数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although biologics are effective in treating psoriasis, a subset of patients experience severe relapse after treatment discontinuation. OBJECTIVE: To delineate the features and risk factors for a distinct pustular psoriasis flare following biologic withdrawal. METHODS: This multicenter study included treatment episodes from patients with psoriasis who responded to and subsequently discontinued biologic therapy between 2011 and 2025. Clinical features of this distinct pustular psoriasis flare were characterized, and associated factors were assessed using a generalized estimating equation model. RESULTS: These pustular psoriasis flares occurred in 86 of 1198 treatment episodes (7.2%) and were characterized by painful, diffuse, intense erythema with pustules and swelling, predominantly involving the lower limbs. The occurrence of these flares increased with a higher number of cycles of biologic withdrawal-relapse episodes. A family history of psoriasis, concomitant psoriatic arthritis, a prior episode of this flare phenotype, a higher number of previous biologic withdrawal-relapse episodes, and longer time to achieve Psoriasis Area and Severity Index 50 during biologic therapy were independently associated with this distinct pustular psoriasis flare. LIMITATIONS: Nonrandomized allocation of treatment and lack of histologic and molecular data. CONCLUSIONS: Vigilant monitoring and early treatment resumption are recommended for patients with risk factors for pustular psoriasis flares after biologic withdrawal.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Chiu HY, Hung SJ, Huang YH, et al. Clinical characteristics and risk factors for a distinct pustular psoriasis flare after withdrawal of biologics in plaque psoriasis. J Am Acad Dermatol. 2026. PMID: 42790781. doi:10.1016/j.jaad.2026.09.082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。